Retatrutide
LY3437943 · Eli Lilly
A once-weekly triple agonist targeting GLP-1, GIP and glucagon.
Selected study results
TRIUMPH-1Mean body-weight reductionBody weight decreased 25% · 80 weeks · Phase 3
Mean body-weight reduction · 80 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight and a complication, without diabetes · Retatrutide 12 mg weekly vs placebo · Trial N=2339 · Treatment-regimen estimand; intention-to-treat analysis in the published randomized Phase 3 trial. Results & methods ↗ · Publication ↗
| Weekly dose | Weight change |
|---|---|
| 4 mg | −17.6% |
| 9 mg | −23.7% |
| 12 mg | −25.0% |
| Placebo | −3.9% |
- Same trial · sponsor efficacy estimandThe sponsor reported 28.3% weight reduction with 12 mg versus 2.2% with placebo at 80 weeks under the efficacy estimand. Follow-up source ↗
Primary weight results use the treatment-regimen estimand. The sponsor efficacy-estimand values are a separate analysis of this same protocol; OSA-substudy outcomes are reported separately.
TRIUMPH-1 OA cohort · knee painWOMAC knee-pain score change (0–10 scale)WOMAC knee-pain score decreased 4.3 points · 80 weeks · Phase 3
WOMAC knee-pain score change (0–10 scale) · 80 weeks
Study focus: Knee osteoarthritis outcomes
Adults with BMI ≥27 and painful knee osteoarthritis, without diabetes · Weekly retatrutide versus placebo · Trial N=574 · Efficacy estimand, as reported in the ACR primary abstract. Results & methods ↗ · Publication ↗
| Arm | Change from baseline |
|---|---|
| Retatrutide 4 mg | −3.66 |
| Retatrutide 9 mg | −4.19 |
| Retatrutide 12 mg | −4.30 |
| Placebo | −2.24 |
Pain and weight outcomes do not establish prevention of structural joint damage or avoidance of joint replacement. Conference efficacy-estimand estimates differ from the journal’s other estimands. TRIUMPH-1 OA is a prespecified cohort of the existing master protocol, not an additional trial; its ACR presentation is scheduled for November 10, 2026.
TRIUMPH-4 · knee painWOMAC knee-pain score change (0–10 scale)WOMAC knee-pain score decreased 4.41 points · 68 weeks · Phase 3
WOMAC knee-pain score change (0–10 scale) · 68 weeks
Study focus: Knee osteoarthritis outcomes
Adults with BMI ≥27 and painful knee osteoarthritis, without diabetes · Weekly retatrutide versus placebo · Trial N=445 · Efficacy estimand, as reported in the ACR primary abstract. Results & methods ↗ · Publication ↗
| Arm | Change from baseline |
|---|---|
| Retatrutide 9 mg | −4.48 |
| Retatrutide 12 mg | −4.41 |
| Placebo | −2.43 |
Pain and weight outcomes do not establish prevention of structural joint damage or avoidance of joint replacement. Conference efficacy-estimand estimates differ from the journal’s other estimands. The ACR abstract was presented November 8, 2026.
Diabetes-focused studies
These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.
TRANSCEND-T2D-2Mean body-weight changeBody weight decreased 20.9% · 80 weeks · Phase 3
Mean body-weight change · 80 weeks
Study focus: Weight change in type 2 diabetes
Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor · Retatrutide 12 mg weekly vs semaglutide 2 mg weekly · Trial N=1298 · Efficacy estimand; Lilly sponsor-reported topline. Results & methods ↗
- Retatrutide 9 mgMean weight change was −19.5% (44.3 lb lost), compared with −9.4% (20.9 lb lost) with semaglutide 2 mg. Retatrutide 12 mg: −20.9% (47.4 lb lost). Efficacy estimand.
- HbA1c at week 80Mean HbA1c decreased by 2.2 percentage points with both retatrutide doses versus 1.8 percentage points with semaglutide 2 mg; efficacy estimand.
- Safety and risk factorsLilly reported greater improvements in triglycerides, non-HDL cholesterol and systolic blood pressure with retatrutide. Gastrointestinal adverse events were common. Dysesthesia occurred in 4.8%, 6.5%, and 2.7% and adverse-event discontinuation in 4.8%, 7.9%, and 2.7% with retatrutide 9 mg, 12 mg, and semaglutide, respectively.
Investigational retatrutide. These are sponsor-reported topline results; complete peer-reviewed data are pending. The efficacy estimand assumes treatment adherence.
TRIUMPH-2Mean body-weight changeBody weight decreased 18.8% · 80 weeks · Phase 3
Mean body-weight change · 80 weeks
Study focus: Weight management with type 2 diabetes
80-week Phase 3 weight-management trial in adults with type 2 diabetes.
Adults with obesity or overweight and type 2 diabetes · 12 mg weekly vs placebo · Trial N=1152 · Treatment-regimen estimand; randomized participants included regardless of treatment discontinuation. Results & methods ↗ · Publication ↗
- Other doses · treatment-regimen estimandMean weight changes at week 80: 4 mg −11.9%; 9 mg −16.8%; placebo −5.1%.
- Same trial · efficacy estimandAt 12 mg, weight change was −20.8% versus −4.0% with placebo under the efficacy estimand, which estimates continued treatment. This is a different analysis of the same trial. Follow-up source ↗
Gastrointestinal adverse events were common. Permanent discontinuation due to adverse events or death occurred in approximately 8% at 12 mg versus 5% with placebo.
TRIUMPH-3Mean body-weight changeBody weight decreased 22.6% · 80 weeks · Phase 3
Mean body-weight change · 80 weeks
Study focus: Weight management with cardiovascular disease
Weight and risk factors improved; cardiovascular-event reduction was not established.
Adults with BMI ≥35 and established cardiovascular disease, with or without diabetes · 12 mg weekly vs placebo · Trial N=1949 · Efficacy estimand; sponsor topline. Results & methods ↗
MACE-3 HR 1.12 (95% CI 0.64–1.96), pooled retatrutide versus placebo; few events limit inference.
TRIUMPH-4Mean body-weight changeBody weight decreased 28.7% · 68 weeks · Phase 3
Mean body-weight change · 68 weeks
Study focus: Weight management with knee osteoarthritis
WOMAC pain improved 4.4 vs 2.4 points at 12 mg.
Adults with obesity/overweight and knee osteoarthritis, without diabetes · 12 mg weekly vs placebo · Trial N=445 · Efficacy estimand; primary ACR abstract (previously sponsor topline). Results & methods ↗ · Publication ↗
These efficacy-estimand weight results are retained separately from the journal’s treatment-regimen analysis and from the WOMAC pain endpoint.
Diabetes-focused studies
These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.
TRANSCEND-T2D-1Mean body-weight changeBody weight decreased 15.3% · 40 weeks · Phase 3
Mean body-weight change · 40 weeks
Study focus: Glycemic control in type 2 diabetes
HbA1c decreased 1.94 vs 0.81 percentage points.
Type 2 diabetes inadequately controlled by diet and exercise; BMI ≥23 · 12 mg weekly vs placebo · Trial N=537 · Treatment-regimen estimand. Results & methods ↗
Phase 2 obesity dose-finding studyMean body-weight change at week 48Body weight decreased 24.2% · 48 weeks · Phase 2
Mean body-weight change at week 48 · 48 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight and a weight-related condition, without type 2 diabetes · 12 mg once weekly vs placebo · Trial N=338 · Least-squares mean; week-48 secondary endpoint. Results & methods ↗ · Publication ↗
- Same study · week-24 primary endpointAt 24 weeks, mean body-weight change was −17.5% with 12 mg and −1.6% with placebo.
At week 24, the primary endpoint showed 17.5% mean weight change with 12 mg and 1.6% with placebo.
Diabetes-focused studies
These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.
Phase 2 type 2 diabetes studyMean body-weight change at week 36 (secondary outcome)Body weight decreased 16.9% · 36 weeks · Phase 2
Mean body-weight change at week 36 (secondary outcome) · 36 weeks
Study focus: Weight change in type 2 diabetes
Adults with type 2 diabetes treated with diet and exercise or stable metformin · 12 mg once weekly vs placebo · Trial N=281 · Least-squares mean; secondary weight outcome. The primary endpoint was HbA1c change at week 24.. Results & methods ↗ · Publication ↗
- Same study · primary HbA1c endpointAt week 24, HbA1c decreased by 2.02 percentage points with retatrutide 12 mg, 0.01 points with placebo, and 1.41 points with dulaglutide 1.5 mg.
The study was designed primarily to assess glycemic control in type 2 diabetes.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Obstructive sleep apnea substudies
Week-80 apnea–hypopnea index (AHI) results use the hybrid-treatment estimand; populations are reported separately. Retatrutide remains investigational.
TRIUMPH-1-OSA · without type 2 diabetes
In 243 adults with moderate-to-severe OSA and overweight or obesity without type 2 diabetes, week-80 mean AHI changes were −22.9, −34.3 and −31.7 events/hour with retatrutide 4, 9 and 12 mg, versus −9.9 with placebo. The placebo-adjusted differences were −13.0, −24.4 and −21.9 events/hour, respectively.
TRIUMPH-2-OSA · with type 2 diabetes
In 448 adults with moderate-to-severe OSA and overweight or obesity with type 2 diabetes, week-80 mean AHI changes were −19.2, −24.7 and −25.4 events/hour with retatrutide 4, 9 and 12 mg, versus −10.3 with placebo. Placebo-adjusted differences were −8.9, −14.4 and −15.1 events/hour, respectively.
Mechanism at a glance
Obesity stage by formulation
Latest: Knee-osteoarthritis results from TRIUMPH-4 and the TRIUMPH-1 OA cohort were published in November 2026. Separate TRANSCEND-T2D-2 sponsor topline and published weight and OSA results remain shown below.
Next: Further weight-management, diabetes, cardiovascular and kidney outcome results from the TRIUMPH and TRANSCEND programs.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies9 records
TRIUMPH-1
Weight managementAdults with obesity or overweight without type 2 diabetes; the master protocol includes osteoarthritis and sleep-apnea substudies. OSA substudy outcomes were published in NEJM in October 2026. Knee-pain outcomes are now shown separately using the primary ACR efficacy-estimand estimates; the related NEJM publication appeared November 8, 2026.
TRIUMPH-2
Weight management with type 2 diabetesAdults with obesity or overweight and type 2 diabetes; the master protocol includes an obstructive-sleep-apnea substudy. OSA substudy outcomes were published in NEJM in October 2026.
TRIUMPH-3
Weight management with cardiovascular diseaseAdults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. This is a weight-loss efficacy study, not a dedicated cardiovascular-outcomes trial.
TRIUMPH-4
Weight management with knee osteoarthritisAdults with obesity or overweight and knee osteoarthritis; weight and knee-pain outcomes. Knee-pain outcomes are now shown separately using the primary ACR efficacy-estimand estimates; the related NEJM publication appeared November 8, 2026.
TRIUMPH-5
Comparative weight managementHead-to-head comparison with tirzepatide in adults with obesity.
TRIUMPH-6
Weight maintenanceMaintenance of weight reduction after a retatrutide lead-in period in adults with obesity.
TRIUMPH-7
Weight management with chronic low-back painAdults with obesity or overweight and chronic low-back pain; studies weight and pain outcomes.
TRIUMPH-8
Weight managementAdults without type 2 diabetes who have obesity or overweight; placebo-controlled weight-management study.
TRIUMPH-9
Weight managementAdults without type 2 diabetes who have obesity or overweight; evaluates dose-escalation approaches.
Phase 2 studies1 record
Phase 2 obesity study
Weight managementAdults with obesity or overweight and weight-related complications, without type 2 diabetes; published dose-ranging study.
Related conditions and outcomes
Phase 3 studies5 records
SYNERGY-Outcomes
Liver outcomes (MASLD)Shared master protocol testing retatrutide and tirzepatide in adults with high-risk MASLD; evaluates major adverse liver outcomes. The two medicines are separate study arms.
TRANSCEND-T2D-1
Glycemic control in type 2 diabetesAdults with type 2 diabetes inadequately controlled by diet and exercise; positive sponsor topline reported in March 2026.
TRANSCEND-T2D-2
Glycemic control in type 2 diabetesAdults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor; retatrutide compared with semaglutide 2 mg. Lilly reported 80-week topline results; full peer-reviewed data are pending.
TRANSCEND-T2D-3
Glycemic control with kidney impairmentAdults with type 2 diabetes and moderate or severe renal impairment with inadequate control on basal insulin, with or without other background therapy.
TRIUMPH-Outcomes
Cardiovascular and kidney outcomesEvent-driven cardiovascular and kidney outcomes in adults with obesity plus established atherosclerotic cardiovascular disease and/or chronic kidney disease.
Phase 2 studies1 record
Phase 2 type 2 diabetes study
Glycemic control in type 2 diabetesPublished placebo- and active-controlled study in adults with type 2 diabetes; distinct from the later TRANSCEND Phase 3 trials.
